Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
Initial Phase 3-focused funding to support advancement of AP-SA02 in complicated Staphylococcus aureus bacteremia New commitment is incremental to previously announced DoW funding and expands total non-dilutive support for the AP-SA02 program to $32.4 million LOS ANGELES, Sept. 23, 2026...